Cartesian Therapeutics (RNAC) Current Deferred Revenue (2015 - 2024)

Cartesian Therapeutics (RNAC) has 10 years of Current Deferred Revenue data on file, last reported at $412000.0 in Q1 2024.

• On a quarterly basis, Current Deferred Revenue fell 90.26% year-over-year to $412000.0 in Q1 2024; TTM through Mar 2024 was $412000.0, a 90.26% decrease from a year earlier, with the FY2023 full-year figure at $2.3 million, up 289.71% from the prior year.
• Current Deferred Revenue for Q1 2024 stood at $412000.0, down from $2.3 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for RNAC reached as high as $115.8 million in Q3 2020 and fell as low as $412000.0 in Q1 2024.
• Historically, Current Deferred Revenue has averaged $34.4 million across 5 years, with a median of $9.2 million in 2021.
• Across the five-year window, Current Deferred Revenue jumped 11223.46% in 2020 and tumbled 93.55% in 2022, its largest moves.
• Year by year, Current Deferred Revenue stood at $110.8 million in 2020, then sank by 91.7% to $9.2 million in 2021, then tumbled by 93.55% to $593000.0 in 2022, then soared by 289.71% to $2.3 million in 2023, then plunged by 82.17% to $412000.0 in 2024.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $412000.0 in Q1 2024, $2.3 million in Q4 2023, and $4.1 million in Q3 2023.